Matrix metalloproteinase inhibitors: Do they have a place in anticancer therapy?

Michelle A. Rudek, Jürgen Venitz, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Matrix metalloproteinases (MMPs) are a family of enzymes involved in degradation of extracellular matrix. An imbalance between MMPs and naturally occurring MMP inhibitors may cause excess extracellular matrix destruction, allowing cancer cells to invade surrounding tissues and metastasize, and permitting angiogenesis to occur. Inhibition of certain key MMPs may prevent angiogenesis, tumor growth, invasion, and metastasis. Gelatinases MMP-2 and MMP-9 are expressed during carcinogenesis and angiogenesis. Synthetic MMP inhibitors were designed to target these enzymes and potentially prevent the tumor growth and metastases associated with cancer.

Original languageEnglish
Pages (from-to)705-720
Number of pages16
Issue number6
StatePublished - 2002
Externally publishedYes


Dive into the research topics of 'Matrix metalloproteinase inhibitors: Do they have a place in anticancer therapy?'. Together they form a unique fingerprint.

Cite this